Dr. Rao on dual PARP/AR inhibition in mCRPC
Arpit Rao, MD, an associate professor of Medical Oncology at Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefit of dual inhibition of the PARP and androgen receptor (AR) pathways in patients with prostate cancer. He also explains that a successful phase 2 trial (doi: 10.1016/S1470-2045(18)30365-6) of the AR pathway inhibitor (ARPI) abiraterone acetate (Zytiga) combined with the PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC) inspired his colleagues and him to launch the CASPAR (Alliance A031902) trial, a randomized phase 3 trial of the ARPI enzalutamide (Xtandi) combined with the PARP inhibitor rucaparib (Rubraca) in patients with mCRPC (NCT04455750).
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Personalized therapeutic approaches in ccRCC remain challenging
April 15th 2024"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.
Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC
April 5th 2024“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.
